Real-world evidence market seen growing at 19% CAGR through 2030

The real-world evidence market is projected to rise from $4.33 billion in 2025 to $10.3 billion by 2030, driven by wider use of electronic health records, insurance claims data, AI, and wearable monitoring. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest over the forecast period.

Why it matters: - Real-world evidence is becoming a bigger part of clinical research, regulatory review and precision medicine. - The market’s growth signals more demand for data drawn from everyday care, not just controlled trials. - Health systems, drugmakers and regulators are increasingly using these data sources to assess treatment effectiveness, safety and utilization.

What happened: - The real-world evidence market is projected to grow from $4.33 billion in 2025 to $5.14 billion in 2026. - The Business Research Company forecasts the market will reach $10.3 billion by 2030. - The report puts the market’s 2026-2030 compound annual growth rate at 19.0%. - The market is driven by digital transformation in healthcare and broader use of data-driven decision-making.

The details: - Real-world evidence draws on electronic health records, insurance claims, patient registries and wearable devices. - The report says adoption of EHRs, healthcare digitization and insurance claims analytics helped accelerate growth in 2026. - Demand for post-market surveillance research is also supporting market expansion. - Expanded patient registries across diseases are adding more longitudinal data for analysis. - Regulatory acceptance of real-world data is increasing, strengthening its role in decision-making. - Looking ahead, AI and machine learning are expected to play a larger role in generating evidence. - Wearable and remote monitoring devices are enabling continuous data collection. - Cloud-based healthcare analytics platforms are gaining share. - Predictive and prescriptive analytics are being used more often to inform regulatory and reimbursement decisions. - The report highlights AI-powered analytics platforms for clinical decision support as a key trend. - It also points to deeper integration of wearable data and machine learning models designed to produce regulatory-grade evidence.

Between the lines: - Precision medicine is one of the clearest demand drivers because treatment decisions increasingly depend on patient-specific factors such as genetics and biomarkers. - Real-world evidence helps show how therapies perform across different patient groups, which matters when safety and outcomes vary in practice. - The rise in FDA approvals for personalized therapies in 2023 suggests the market for evidence tied to tailored treatment is expanding. - North America held the largest market share in 2025 because of advanced healthcare infrastructure and supportive regulatory frameworks. - Asia-Pacific is expected to be the fastest-growing region as healthcare systems expand data use and analytics capabilities.

What's next: - The market is expected to keep expanding as healthcare organizations connect more data sources and adopt AI-enabled analytics. - Greater use of wearables and remote monitoring could make evidence generation more continuous and more granular. - Broader regulatory and reimbursement use of real-world evidence may increase demand for standardized, regulatory-grade analytics. - The report also says its 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspots infographics, and updated trend analysis.

The bottom line: - Real-world evidence is moving from a supporting tool to a core input for drug development, regulation and personalized care.